Latest advances in adult gastrointestinal stromal tumors

Vaia Florou, Breelyn A. Wilky, Jonathan C. Trent

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFRα mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFRα mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.

Original languageEnglish (US)
Pages (from-to)2183-2193
Number of pages11
JournalFuture Oncology
Issue number24
StatePublished - Oct 2017


  • GIST
  • KIT
  • PDGFRα
  • circulating tumor DNA
  • quadruple WT GIST

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Latest advances in adult gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this